Romiplostim (AMG531) is a thrombopoietin agonist, platelet growth factor that stimulates platelet production by binding to the myeloproliferative leukaemia receptor. It increases the production of platelets by stimulating the differentiation and proliferation of megakaryocytes. It is also in phase II trials for chemotherapy induced thrombocytopenia and myelodysplastic syndrome. Developer Amgen Stage of development and availability in EU/UK Pre-registration in EU (drugs) CE marked, but not yet launched Phase III clinical trials or or available in UK equivalent Licence or CE mark application in Launch or use in UK/EU likely Licence or CE mark application UK/EU likely within 24 months within 12 months in UK/EU likely within 12 months Established product, but this is a Other, please specify Launch or use in UK/EU likely new indication in development within 24 months
Ropeginterferon alfa-2b for injection is under development for the treatment of polycythaemia vera (PV), a rare blood disease in which the body makes too many red blood cells. The extra red blood cells make the blood thicker than normal and as a result, blood clots can form more easily. These clots may block blood flow through arteries and veins, which can cause a heart attack or stroke. Thicker blood also does not flow as quickly and may prevent organs from getting enough oxygen. A mutation, or change, in a gene called JAK2 is the major cause of PV. This gene makes a protein that helps the body produce blood cells. PV develops slowly and may not cause symptoms for years. PV has no cure, but treatments can help control the disease and its complications.